A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
BioNTech SE
Merck Sharp & Dohme LLC
OncoC4, Inc.
Merck Sharp & Dohme LLC
Imugene Limited
AstraZeneca
DualityBio Inc.
Genfit
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Elicio Therapeutics
Leap Therapeutics, Inc.
Shanghai Bao Pharmaceuticals Co., Ltd.
Lisata Therapeutics, Inc.
Pfizer
Elevation Oncology
Intensity Therapeutics, Inc.
PureTech
Erbe Elektromedizin GmbH
Carisma Therapeutics Inc
Beijing Biostar Pharmaceuticals Co., Ltd.
UTC Therapeutics Inc.
Celldex Therapeutics
Basilea Pharmaceutica
Novo Nordisk A/S
Chongqing Precision Biotech Co., Ltd
PCI Biotech AS
Klus Pharma Inc.
Xencor, Inc.
Delcath Systems Inc.
MacroGenics
Senhwa Biosciences, Inc.
Curegenix Inc.
PCI Biotech AS
Concordia Laboratories Inc.
Shanghai Golden Leaf MedTec Co. Ltd
Galectin Therapeutics Inc.
Taewoong Medical Co., Ltd.
INSYS Therapeutics Inc
Delcath Systems Inc.
Daiichi Sankyo
Helsinn Healthcare SA